ICMJE DISCLOSURE FORM

Date:			12/26/2024					
Your Name:			Michel MRF Struys					
Manuscript Title:			Pijnstilling tijdens de baring; indicaties, voor- en nadelen voor patiënt en neonaat					
Manuscript Number (if known):			D8441					
cor affe	tent of your manuscrected by the content of	ript. "Rela of the ma						
The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.								
	In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.							
			ll entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)				
			Time frame: Since the initial planning o	of the work				
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		one	Click the tab key to add additional rows.				
	Time frame: past 36 months							
2	Grants or contracts from any entity (if not indicated in item #1 above).	His reso the last fees fro Dickins (Bad Ho	earch group/department received (over t 3 years) research grants and consultancy om Masimo (Irvine, CA, USA), Becton son (Eysins, Switzerland), Fresenius-Kabi omburg, Germany), Paion (Aachen, ny), Medcaptain Europe (Andelst, The					

Netherlands), Baxter (Chicago, II, USA), Eagle Pharmaceuticals Inc (Woodcliff, New Jersey, USA),

HanaPharm (Seoul, Republic of Korea).

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	□ None Gent University, Gent, Belgium Demed, Sinaai, Belgium	
4	Consulting fees	□ None See 2	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	□ None Harvard Anesthesiology Update Course Euroanaesthesia ASA	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None ESAIC BJA	
œ	Patents planned, issued or pending	U.S. patent number 9,757,045 [Application Number 11/044,445] U.S. patent number US20200253544A1 and US12076159B2 [Application Number US16/784,067]	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	

ľ		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	□ None ESAIC (Chair Scientific Committee) Trustee BJA (British Journal of Anaesthesia Associate Editor Anesthesiology	Editorial Board member Clinical Pharmacokinetics		
	options				
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	See 2, connected to grants			
13	Other financial or non-financial interests	None			
Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.					